Home › Essential Thrombocythemia
Essential Thrombocythemia clinical trials recruiting in the U.S.
16 studies for Essential Thrombocythemia are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY7 studies
- Durham, NC6 studies
- Baltimore, MD4 studies
- Boston, MA4 studies
- Mountain View, CA4 studies
- Nashville, TN4 studies
- Miami, FL4 studies
- Salt Lake City, UT4 studies
- Chicago, IL4 studies
- St. Louis, MO3 studies
- Houston, TX3 studies
- Cleveland, OH3 studies
- Kansas City, MO3 studies
- Los Angeles, CA3 studies
- Columbus, OH3 studies
- Irvine, CA3 studies
By state
- California7 studies
- Florida5 studies
- Illinois4 studies
- Kansas3 studies
- Maryland4 studies
- Massachusetts4 studies
- Missouri3 studies
- New York7 studies
- North Carolina8 studies
- Ohio5 studies
- Pennsylvania4 studies
- Tennessee4 studies
- Texas4 studies
- Utah4 studies
Recently updated studies
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06661915Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07623200A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT06351631Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06063486An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 10, 2026 · NCT05123365MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 23, 2026 · NCT07362225Ruxolitinib in Thrombocythemia and Polycythemia Vera
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 8, 2026 · NCT04644211MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT06541249Two Step Haplo With Radiation Conditioning
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2025 · NCT05031897Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 3, 2024 · NCT06218628From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.